- In general after long-term maintenance treatment, the best is to reduce the dose by about 25% every 4-6 weeks. An apt pharmaceutical dose (tablet, capsule, mixture) is not always available. In these cases one should be creative with dosing.
- Another, more risky, possibility is being at a certain dose to use the following scheme::
- 30 mg/day :
- Day 1: reduce dosage of paroxetine to 20 mg/day.
- Day 8: reduce dosage of paroxetine to 10 mg/day.
- Day 15: reduce dosage of paroxetine to 5 mg/day (preferably in 2 doses).
- Day 22: reduce dosage of paroxetine to 2,5 mg/day (preferably in 2 doses).
- Day 29: stop administration of paroxetine.
- The UK Drug and Therapeutics Bulletin; 1999;37:49-52
- Editor: please note that not all dosages are available in pharmacy. So now and then you should be creative.
- Rosenbaum JF et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998 Jul 15;44(2):77-87
- Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24(3):183-97
- Moleman P, Geneesmiddelen voor de geest: een praktische gids. Amsterdam: Nieuwezijds; 2007. p.225.(Dutch)
- Bazire S, Psychotropic Drug Directory 2010. Aberdeen: HealthComm UK Ltd; 2010.
- Himei A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs. 2006;20(8):665-72
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.